FDA gastrointestinal panel meeting scheduled for Salix's Xifaxan
This article was originally published in Scrip
Executive Summary
A US FDA gastrointestinal drugs advisory meeting has been scheduled for February 23rd, 2010, to discuss Salix Pharmaceuticals' Xifaxan (rifaximin), which has been filed for maintenance of remission of hepatic encephalopathy.